ClinicalTrials.gg
RecruitingNCT06522555Updated Aug 5, 2024

The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

A Phase 3 interventional study of polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide and zanubrutinib, rituximab and lenalidomide in Diffuse Large B-Cell Lymphoma, sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2024-08-05.

Sponsored by Ruijin Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing polatuzumab vedotin in Lymphoma, Large B-Cell, Diffuse — 15 open to participants now, 18 under way, 1 of them phase 3. polatuzumab vedotin · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
8th of 28
100 · median 42
Started
2024
with 3 others
Phase 3
5 of 28
1 open now
Primary completion
2028-08
later than 11 of 17 live
Registered
19th of 28
by date

Among the 28 studies testing polatuzumab vedotin in Lymphoma, Large B-Cell, Diffuse, this one is the 8th largest by planned enrollment, is one of 4 that started in 2024, is one of 5 in phase 3, reaches primary completion later than 11 of the 17 other live ones, and was the 19th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

15 of the 28 studies testing polatuzumab vedotin in Lymphoma, Large B-Cell, Diffuse are open now, in 2 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About polatuzumab vedotin

polatuzumab vedotin: first FDA approval 2019 (POLIVY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing polatuzumab vedotin in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of Pola-ZR2 (polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide) versus ZR2 (zanubrutinib, rituximab and lenalidomide) in the treatment of old patients with de novo diffuse large B-cell lymphoma

Read the detailed description

This study will evaluate the efficacy and safety of Pola-ZR2 versus ZR2 in the treatment of elderly de novo diffuse large B-cell lymphoma patients. Subjects will be randomly assigned 1:1 to Pola-ZR2 or ZR2 regimen. The stratification will be performed according to international prognostic index (2-3 / 4-5).

Patients in Pola-ZR2 group will receive 6 cycles of polatuzumab vedotin 1.8 mg/kg, day 2 on the 1st cycle and day 1 on the 2nd to 6th cycle, zanubrutinib 160mg bid, day 1-21, orally, lenalidomide 25mg qd, day 2-11, orally, rituximab 375mg/m², day 1, intravenously, every 21 days. Patients in ZR2 group will receive 6 cycles of zanubrutinib 160mg bid, day 1-21, orally, lenalidomide 25mg qd, day 2-11, orally, rituximab 375mg/m², day 1, intravenously, every 21 days.

Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma

Keywords

  • diffuse large B-cell lymphoma
  • polatuzumab vedotin
  • zanubrutinib
  • lenalidomide
  • rituximab
  • old patients
  • unfit
  • frail
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must satisfy all of the following criteria to be enrolled in the study:

  • -confirmed diffuse large B-cell lymphoma (without central nervous system involvement)
  • Aged ≥ 80 years old or aged 70-79 with comprehensive geriatric assessment stratified as unfit or frail
  • International prognostic index score 2 to 5
  • At least 1 measurable site of disease (defined as lymph nodes with the long diameters longer than 1.5cm, or extra-nodal sites with the long diameters longer than 1.0cm; meanwhile, any lesion site with at least 2 measurable vertical diameters)
  • Able to swallow capsules
  • of at least 3 months determined by researchers
  • The patient or his or her legal representative must provide written prior to any special examination or procedure for the research.
  • Anti-lymphoma drugs have not been used before (except )

Exclusion criteria

Exclusion Criteria:

Presence of any of the following criteria will exclude a patient from enrollment:

  • Uncontrolled blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases
  • Laboratory measures meet the following criteria at screening (unless caused by lymphoma):

Neutrophils\<1.5×10\^9/L \<80×10\^9/L or AST is 2 times higher than the (ULN), serum are 1.5 times higher than the ULN.

Creatinine is 1.5 times higher than the ULN or is lower than 40ml/min/1.73m\^2 (according to Equation or MDRD Equation).

  • uncontrollable or significant cardiovascular diseases, including but not limited to: \<50% Cardiomyopathy, such as dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy prolongation with clinical significance, QTc interval>470ms (females) or 480ms (males), type 2 second-degree atrioventricular block or third-degree atrioventricular block
  • Patients with HbsAg positive are required to have \<1.0×10\^3 IU/ml before entering the group. In addition, if the patient is HBsAg negative but HBcAb positive (regardless of HBsAb status), HBV DNA test is also required, and HBV DNA\<1.0×10\^3 IU/ml is required before entering the group
  • Patients with psychiatric disorders or patients who are known or suspected to be unable to fully comply with the study protocol
  • -infected patients
  • History of stroke or intracranial hemorrhage within 6 months prior to start of therapy
  • Other medical conditions determined by the researchers that may affect the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Pola-ZR2

    six courses of polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide induction therapy and lenalidomide maintenance therapy

    Drug: polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide

  • Active comparator
    ZR2

    six courses of zanubrutinib, rituximab and lenalidomide induction therapy and lenalidomide maintenance therapy

    Drug: zanubrutinib, rituximab and lenalidomide

Interventions

  • Drugpolatuzumab vedotin, zanubrutinib, rituximab and lenalidomide

    Drug pages: Polatuzumab vedotinStudies of Polatuzumab vedotinPolatuzumab vedotin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ZanubrutinibStudies of ZanubrutinibZanubrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · RituximabStudies of RituximabRituximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LenalidomideStudies of LenalidomideLenalidomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: Polatuzumab vedotin, Zanubrutinib, Lenalidomide and Rituximab (Pola-ZR2) Induction therapy: The Pola-ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles. Dosage: Polatuzumab vedotin 1.8 mg/kg, day 2 on the 1st cycle and day 1 on the 2nd to 6th cycle; Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1. Maintenance therapy: Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years.

  • Drugzanubrutinib, rituximab and lenalidomide

    Drug pages: ZanubrutinibStudies of ZanubrutinibZanubrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · RituximabStudies of RituximabRituximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LenalidomideStudies of LenalidomideLenalidomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: Zanubrutinib, Lenalidomide and Rituximab (ZR2) Induction therapy: The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles. Dosage: Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1. Maintenance therapy: Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years.

06

What researchers measure

Primary outcomes

  1. 2-year PFS rate

    Time frame: up to approximately 2 years

Secondary outcomes

  1. Progression free survival

    Progression-free survival was defined as the time from the date of randomization until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.

    Time frame: Baseline up to data cut-off (up to approximately 2 years)

  2. 2-year OS rate

    2-year OS rate

    Time frame: Baseline up to data cut-off (up to approximately 2 years)

  3. Overall survival

    Overall survival was defined as the time from the date of randomization to the date of death from any cause.

    Time frame: Baseline up to data cut-off (up to approximately 2 years)

  4. Complete response rate

    Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

    Time frame: End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6 [Cycle length=21 days]]

  5. Overall response rate

    Percentage of participants with complete or partial response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

    Time frame: End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6 [Cycle length=21 days]]

  6. Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: From enrollment to study completion, a maximum of 5 years

  7. Percentage of Participants Achieving Meaningful Improvement in European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30)

    Quality of Life will be assessed by EORTC QLQ-C30 (Verison 3.0).

    Time frame: Day 1 of Cycles 1 and 4 (Cycle length=21 days); 30 days after treatment completion

  8. Percentage of Participants Achieving Meaningful Improvement in EORTC QLQ-ELD14 (Elderly Module)

    Quality of Life will be assessed by EORTC QLQ-ELD14.

    Time frame: Day 1 of Cycles 1 and 4 (Cycle length=21 days); 30 days after treatment completion

  9. Percentage of Participants Achieving Meaningful Improvement in Functional Assessment of Cancer Therapy-Lymphoma Lymphoma Subscale (FACT-Lym LymS)

    Quality of Life will be assessed by FACT-Lym LymS.

    Time frame: Day 1 of Cycles 1 and 4 (Cycle length=21 days); 30 days after treatment completion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Aug 2028, 48 months after the start.

Of 73 phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 99. This study's planned 48 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2024
First posted
Jul 26, 2024
StartActual
Jul 29, 2024
Primary completionEst.
Aug 10, 2028
CompletionEst.
Aug 10, 2029
Last update
Aug 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06522555
Lead sponsor
Ruijin Hospital
Responsible party
Zhao Weili (Professor and Director, Shanghai Institute of Hematology, Ruijin Hospital) — Principal investigator
First posted
Jul 26, 2024
Start date
Jul 29, 2024
Primary completion
Aug 10, 2028 (estimated)
Completion
Aug 10, 2029 (estimated)
Last update
Aug 5, 2024

Study contacts

Weili Zhao
Contact
zwl_trial@163.com
+862164370045 ext. 610707
Li Wang
Contact
wl_wangdong@126.com
+862164370045 ext. 610707

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Polatuzumab vedotin · Zanubrutinib · Rituximab · Lenalidomide

Start the discussion